Yuji Habu | Gynecology | Best Researcher Award

Posted on by Academic achievements

Assist. Prof. Dr. Yuji Habu | Gynecology | Best Researcher Award

Assist. Prof. Dr. Yuji Habu | Gynecology – Assistant Professor at Department of Obstetrics and Gynecology, Chiba University Hospital, Japan

Dr. Yuji Habu is an accomplished academic and clinical researcher specializing in Obstetrics and Gynecology. With a robust background in both medical practice and research, he is currently an Assistant Professor in the Department of Obstetrics and Gynecology at Chiba University Hospital. His work focuses on women’s health, particularly in the areas of gynecologic oncology, early detection, and cancer treatment innovations. Known for his interdisciplinary approach and commitment to improving patient outcomes, Dr. Habu has become a leading figure in his field. He has significantly contributed to numerous studies, offering insights that shape both clinical practices and academic knowledge globally.

Profile:

Orcid

Education:

Dr. Habu’s educational journey began with his medical studies at Kanazawa University, where he earned his Medical Degree (MD) in 2008. He pursued his doctoral studies at Chiba University, earning a PhD in 2022 from the Graduate School of Medical and Pharmaceutical Sciences. His academic excellence has laid a solid foundation for his clinical career and research endeavors. The comprehensive education provided him with both the theoretical and practical knowledge necessary to address complex medical challenges, particularly in the realms of gynecologic cancers and women’s reproductive health.

Experience:

Dr. Habu’s career spans across various roles, beginning with his initial work as a Resident in Internal Medicine at Yokosuka General Hospital in 2008. He later transitioned into Obstetrics and Gynecology, working in multiple hospitals, including Chiba University Hospital and Kimitsu Chuo Hospital. His roles as a Senior Resident and Clinical Staff Physician have equipped him with the hands-on experience needed to complement his research. In 2019, he became an Assistant Professor at Chiba University Hospital, where he currently leads both clinical and research initiatives. His diverse experience across multiple institutions has enabled him to develop a well-rounded perspective on patient care and medical research.

Research Interests:

Dr. Habu’s research interests are primarily centered around gynecologic oncology, focusing on the early detection, treatment, and management of cancers such as cervical, endometrial, and ovarian cancers. He is particularly interested in innovative diagnostic techniques, such as the use of sentinel lymph node mapping in cancer surgeries, and exploring new therapeutic approaches. His work has also extended to examining the long-term outcomes of fertility-sparing treatments for endometrial hyperplasia and cancer. Dr. Habu has contributed to research on using advanced imaging techniques like diffusion-weighted MRI to predict prognosis in uterine cervical cancer patients, as well as evaluating new treatment regimens in ovarian cancer survivors.

Awards and Recognition:

Dr. Habu has been recognized for his significant contributions to medical research and patient care, particularly in the fields of obstetrics and gynecology. His innovative research in cancer treatments and diagnostic techniques has earned him multiple accolades. As a highly regarded specialist and leader in his field, he has received national recognition through board certifications from various prestigious societies, including the Japanese Society of Internal Medicine and the Japan Society of Obstetrics and Gynecology. His ongoing work continues to pave the way for advances in gynecologic oncology.

Publications:

Dr. Habu has authored a number of high-impact research articles that have contributed to the advancement of gynecologic oncology. Here are a few key publications:

  1. Habu Y, Usui H, Hanawa S, et al. Evaluation of the usefulness of sentinel lymph node mapping using indocyanine green in patients with cervical and endometrial cancers: A single-center prospective exploratory study. J Obstet Gynaecol Res. 2025;51(2):e16254. 📄
    Cited by multiple articles in gynecological oncology, emphasizing innovative cancer staging techniques.
  2. Matsuoka A, Tate S, Nishikimi K, et al. Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series. J Obstet Gynaecol Res. 2024;50:1148-54. 📄
    This research has been cited in studies exploring long-term effects of cancer therapies on survivors.
  3. Okonogi N, Murata K, Yamada S, et al. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results. Int J Mol Sci. 2023;24(13):10565. 📄
    Highly cited in immunotherapy and radiotherapy research, showing promise in advanced cervical cancer treatment.
  4. Takada A, Yokota H, Nemoto MW, et al. Prognosis prediction of uterine cervical cancer using changes in histogram and texture features of apparent diffusion coefficient during definitive chemoradiotherapy. PLoS One. 2023;18:e0282710. 📄
    Widely referenced in research on imaging biomarkers for predicting cancer prognosis.
  5. Tamura M, Uzawa A, Kitayama Y, et al. Multiple cerebral infarctions complicating deep vein thrombosis associated with uterine adenomyosis: A case report and literature review. Cureus. 2022;14:e28061. 📄
    Cited by multiple studies examining rare complications in gynecologic diseases.
  6. Mitsuhashi A, Ishikawa H, Habu Y, et al. The effect of steep head-down tilt on respiratory status in endometrial cancer patients with obesity during robot-assisted hysterectomy. Gynecol Oncol Rep. 2022;41:101014. 📄
    Cited in surgical oncology literature on improving surgical outcomes in high-risk patients.
  7. Habu Y, Mitsuhashi A, Hanawa S, et al. High prevalence of pulmonary embolism prior to cancer therapies in patients with ovarian and endometrial cancers detected by contrast-enhanced CT using D-dimer as an index. J Surg Oncol. 2021;124:106-14. 📄
    This study has influenced preoperative protocols for gynecologic cancer patients.

Conclusion:

Dr. Yuji Habu is an exceptional researcher whose work in gynecologic oncology has had a profound impact on clinical practices and patient care. His research has contributed significantly to improving cancer treatments, particularly in the areas of diagnosis, prevention, and post-treatment management. With a consistent track record of high-quality publications and a dedication to advancing women’s health, Dr. Habu is a deserving candidate for the “Best Researcher Award.” His contributions continue to push the boundaries of medical knowledge and will undoubtedly shape the future of gynecological cancer treatment.

Marcelo Custodio | Womens Health | Visionary Research Impact Award

Posted on by Academic achievements

Dr. Marcelo Custodio | Womens Health | Visionary Research Impact Award 

Global Medical Manager | Abbott | Switzerland

Based on Marcelo Graziano Custodio’s extensive background and accomplishments, here’s an analysis for the Research for Visionary Research Impact Award:

Strengths for the Award:

  1. Leadership in Medical Affairs: Marcelo has held pivotal roles in leading medical teams across multiple pharmaceutical companies (Abbott, AstraZeneca, Merck Serono), demonstrating his ability to drive strategic initiatives and achieve significant milestones in therapeutic areas like Women’s Health, Onco-Hematology, and Oncology.
  2. Global Impact: His work spans international boundaries, contributing to global leadership in menopause treatment and reproductive health. Marcelo’s efforts in expanding geographical reach (Asia-Pacific, Latin America) highlight his strategic acumen and execution capabilities.
  3. Scientific Contributions: Marcelo has been involved in numerous scientific publications and presentations, focusing on topics ranging from ultra-low-dose hormone therapies to economic evaluations in oncology. His contributions to clinical research and real-world data generation underscore his commitment to advancing medical knowledge.
  4. Professional Recognition: Marcelo has received multiple internal awards at Abbott for scientific leadership, teamwork, and excellence in medical affairs. These accolades reflect his peers’ and leaders’ acknowledgment of his contributions and impact within the industry.
  5. Educational and Training Initiatives: He has developed continuous medical education programs in collaboration with global medical societies, emphasizing his dedication to advancing medical knowledge and training future medical professionals.

Areas for Improvement:

  1. Broader External Recognition: While Marcelo has received internal awards, external recognition through industry-wide awards or peer-reviewed publications could further enhance his profile and influence in the field.
  2. Diversification of Therapeutic Areas: While Marcelo has significant expertise in Women’s Health and Oncology, further expanding into other therapeutic areas could broaden his impact and relevance in the pharmaceutical industry.
  3. Public Engagement and Advocacy: Increasing visibility through speaking engagements, panel discussions, or thought leadership articles could amplify his influence on critical healthcare issues beyond the pharmaceutical sector.

Conclusion:

Marcelo Graziano Custodio is a highly accomplished medical affairs professional with a robust track record in pharmaceutical leadership, global medical initiatives, and scientific contributions. His strategic insights, combined with a commitment to advancing medical education and clinical research, make him a strong candidate for the Research for Visionary Research Impact Award. Enhancing external visibility and diversifying therapeutic expertise could further solidify his position as a leader in the global healthcare landscape.

Short Biography 🌟

Marcelo Graziano Custodio, MD TEGO MSc MBA, is a Brazilian-Italian medical professional with extensive expertise in pharmaceuticals, specializing in Oncology, Onco-Hematology, and Women’s Health. Currently serving as Global Women’s Health Medical Lead at Abbott, he has driven significant advancements in medical affairs and clinical research across multiple continents.

Profile

SCOPUS

Education 📚

Marcelo Graziano Custodio pursued his Medical Degree and subsequent residency in Gynecology & Obstetrics at the University of Sao Paulo, Brazil. He furthered his academic journey with an Expert certification from the Brazilian Federation of Gynecology and Obstetrics (TEGO) and a Master of Science in Gynecology & Obstetrics from the University of Sao Paulo. His educational achievements culminated in an MBA in Strategic Management from Fundação Getúlio Vargas in collaboration with Ohio University, where he earned the Best Student Award.

Experience 💼

Marcelo has accumulated diverse experience in the pharmaceutical industry, notably as the Global Women’s Health Medical Lead at Abbott, where he spearheaded groundbreaking initiatives in Menopause treatment and reproductive health. His previous roles include Onco-Hematology Medical Lead at AstraZeneca and positions at Eurofarma and Merck Serono, focusing on therapeutic portfolio management and strategic medical affairs.

Research Interest 🧬

His research interests span the spectrum of Women’s Health, Oncology, and clinical data generation, emphasizing safety and efficacy in hormonal therapies, endometriosis, and other gynecological disorders. Marcelo actively contributes to scientific advancements through collaboration with global medical societies and continuous medical education programs.

Award 🏆

Marcelo Graziano Custodio has been recognized with numerous awards, including Abbott’s Excellence Awards for his leadership and scientific contributions in Women’s Health, Menopause treatment, and evidence-based medicine. His accolades underscore his commitment to innovation and medical excellence.

Publication 📄

Publication: Teich V, Custodio MG, Laloni MT, Costa MADSB, Campolina AG, Holtz L, Oliveira M, Bortoleto N, Salgado J. A Multicriteria Decision Analysis (MCDA) to Evaluate Alternative Treatments for Locally Advanced or Metastatic EGFR Positive Non-Small Cell Lung Cancer under the Brazilian Private Healthcare System Perspective. Value in Health. 2019; 22(Suppl 2): S98.

Publication: Ferreira CG, Custodio M, Montenegro G, Caetano R, Bonan L. Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil. Journal of Thoracic Oncology. October 2018; 13(10): S676–S677.

Publication: Ferreira CG, Zallis M, Zukin M, Castro Jr. G, Mathias C, Haddad CK, de Lima VCC, Araújo LH, Baldotto C, Gelatti A, Bustamante C, Custodio MG, Montenegro GT, de Souza AG, Reis M. Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients – A National-Wide Study. Journal of Thoracic Oncology. October 2018; 13(10): S676.

Publication: Cronemberger E, Baldotto C, Marinho F, De Marchi P, Araújo LH, Franke F, Salles P, Calabrich A, Almeida T, Custodio MG, Araujo C, Horacio M, Castro Jr G. EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil. Journal of Thoracic Oncology. October 2018; 13(10): S871–S872.

Publication: Araújo LH, Castro Jr G, De Marchi P, Baldotto C, Werutsky G, Borges G, Mathias C, Calabrich A, Costa C, Franke F, Lima E, Neron Y, Schwartsmann G, Custodio MG, Sansevero C, Freitas HC. Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials. Journal of Thoracic Oncology. October 2018; 13(10): S801.